Skip to main content
. 2023 Nov 4;12(21):2575. doi: 10.3390/cells12212575

Figure 4.

Figure 4

Biological evaluation of generation 6 (A64–A68) and generation 7 (A70–A77) RXR agonists via a CTCL cell proliferation assay. Human cutaneous T-cell lymphoma (Hut78) cells were plated at 10,000–20,000 cells per well and immediately dosed with either the ethanol vehicle or 10 μM of bexarotene or the indicated analog for 72 h. After 72 h, an MTS assay was performed. The RXR-mediated growth inhibition of bexarotene and each analog, measured as the inverse of the amount of light absorbed at 490 nm, was compared to that of the ethanol vehicle which was set to 100% proliferation activity to serve as the negative control. Bexarotene produced an 85% reduction in cell proliferation. Analogs A71, A72, A74, A76, and A77 produced a complete or almost complete termination of cell proliferation that was statistically significantly lower than bexarotene (* p < 0.05). The data represent averages of three independent experiments.